SARS-CoV-2 mRNA Vaccination Induces Reduced T-Cell Apoptosis in Patients with Solid Tumors
International Journal of Molecular Sciences · 10.07.2026 · 27 (14) · 6173
DOI: 10.3390/ijms27146173 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.07.2026. Verfasst von Ana Belda-Marco und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Molecular Oncology Laboratory, Arnau de Vilanova Hospital, FISABIO, 46015 Valencia, Spain. Hauptthemen laut MEDLINE: Apoptosis, Neoplasms, COVID-19, SARS-CoV-2. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU Operational Program of the European Regional Development Fund (ERDF) for the Valencian Community 2014-2020, Consellería de Sanitat Universal i Salut Pública.
Abstract (Originalsprache)
Messenger RNA (mRNA) vaccines represent a transformative platform in vaccinology, with applications extending beyond SARS-CoV-2 to other infectious diseases and cancer immunotherapy. However, patients with solid tumors receiving active anticancer treatment were largely underrepresented in pivotal vaccination trials, limiting understanding of vaccine-induced immunity in this population. In this prospective exploratory study, we assessed humoral and cellular immune responses after two doses of SARS-CoV-2 mRNA vaccines in 39 patients with solid tumors undergoing active treatment. Blood samples were collected before vaccination and approximately two months after the second vaccine dose, prior to the next treatment cycle. Anti-spike IgG, neutralizing antibodies, receptor-binding domain (RBD) levels, interleukin-6 (IL-6), hematological parameters, immune cell subsets, T-cell differentiation, and early apoptosis in αβ and γδ T-cell subsets were analyzed. Vaccination induced a robust humoral response, with high post-vaccination anti-spike IgG levels (median 988.69 BAU/mL), 97.44% seropositivity, 96.88% true seroconversion among baseline IgG−/NAb− patients, and strong neutralizing antibody activity (median 85.73%). Hematological parameters and IL-6 levels remained broadly stable, suggesting no detectable increase in systemic inflammation during the study period. Cellular analyses identified a reduction in peripheral CD19+ B-cell frequencies and decreased early apoptosis, particularly in CD8+ T cells and CD3+CD56+ NKT-like cells. Although changes in T-cell frequencies and differentiation profiles were also observed, these findings were attenuated after exclusion of participants with possible prior SARS-CoV-2 exposure and should be interpreted as exploratory. Overall, these results show that patients with solid tumors receiving active treatment can mount robust humoral responses to SARS-CoV-2 mRNA vaccination and suggest measurable post-vaccination changes in lymphocyte dynamics, including reduced early T-cell apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Molecular Oncology Laboratory, Arnau de Vilanova Hospital, FISABIO, 46015 Valencia, Spain.
- Department of Mathematics and Computation, Superior Polytechnic School, University of Burgos, 09006 Burgos, Spain.
- Department of Quantitative Methods, Universidad Loyola Andalucía, 41704 Sevilla, Spain.
- Department of Microbiology, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
- Department of Clinical Analysis, Arnau de Vilanova Hospital, 46015 Valencia, Spain.
- Flow Cytometry Unit, Central Unit for Research in Medicine (UCIM), University of Valencia, 46010 Valencia, Spain.
ORCID-Profile: Ana Belda-Marco, Andrés Moret, Carlos Fresneda-Portillo, María Victoria Domínguez-Márquez, Beatriz Jávega, Juan Carlos Andreu-Ballester, Antonio Llombart-Cussac, María Leonor Fernández-Murga
Förderung
- EU Operational Program of the European Regional Development Fund (ERDF) for the Valencian Community 2014-2020
- Consellería de Sanitat Universal i Salut Pública
Zitieren
APA
Belda-Marco, A., Serrano-García, L., Moret, A., Fresneda-Portillo, C., Domínguez-Márquez, M. V., Comes-Raga, A., Jávega, B., O'Connor, J. E., Andreu-Ballester, J. C., Llombart-Cussac, A., & Fernández-Murga, M. L. (2026). SARS-CoV-2 mRNA Vaccination Induces Reduced T-Cell Apoptosis in Patients with Solid Tumors. International Journal of Molecular Sciences, 27(14), 6173. https://doi.org/10.3390/ijms27146173
Vancouver
Belda-Marco A, Serrano-García L, Moret A, Fresneda-Portillo C, Domínguez-Márquez MV, Comes-Raga A, et al. SARS-CoV-2 mRNA Vaccination Induces Reduced T-Cell Apoptosis in Patients with Solid Tumors. International Journal of Molecular Sciences. 2026;27(14):6173. doi:10.3390/ijms27146173
BibTeX
@article{BeldaMarco2026,
author = {Belda-Marco, Ana and Serrano-García, Lucía and Moret, Andrés and Fresneda-Portillo, Carlos and Domínguez-Márquez, María Victoria and Comes-Raga, Ana and Jávega, Beatriz and O'Connor, José-Enrique and Andreu-Ballester, Juan Carlos and Llombart-Cussac, Antonio and Fernández-Murga, María Leonor},
title = {SARS-CoV-2 mRNA Vaccination Induces Reduced T-Cell Apoptosis in Patients with Solid Tumors},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {14},
pages = {6173},
doi = {10.3390/ijms27146173}
}
EUVIMED